Cellectis (NASDAQ:CLLS) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a research note published on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Cellectis Stock Performance

Shares of NASDAQ CLLS opened at $2.85 on Tuesday. The company has a market cap of $158.40 million, a P/E ratio of -1.66 and a beta of 3.08. The firm’s fifty day moving average is $2.74 and its two-hundred day moving average is $2.83. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.50 and a current ratio of 1.50. Cellectis has a 52-week low of $0.96 and a 52-week high of $3.77.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Monday, April 29th. The biotechnology company reported ($0.64) earnings per share for the quarter. Cellectis had a negative net margin of 1,087.66% and a negative return on equity of 99.88%. The business had revenue of $1.99 million during the quarter. As a group, analysts anticipate that Cellectis will post -1.06 EPS for the current fiscal year.

Institutional Trading of Cellectis

An institutional investor recently raised its position in Cellectis stock. Principal Financial Group Inc. increased its position in shares of Cellectis S.A. (NASDAQ:CLLS) by 6.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 424,533 shares of the biotechnology company’s stock after buying an additional 24,906 shares during the period. Principal Financial Group Inc. owned about 0.76% of Cellectis worth $1,125,000 at the end of the most recent quarter. 63.90% of the stock is owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.